However, unlike in the cells treated with siRNAs alone, at the latest time point of the treatments involving virus infection, the mRNA levels of MxB (Fig 5E) and TLR3 (Fig 5F) were significantly different from mock treatment, when subjected to the antiviral siRNAs or GFP-specific siRNA. This evidence concerns the gene TLR3 and viral infectious disease.